RT Journal Article
T1 Utility of circulating serum miRNA profiles to evaluate the potential risk and severity of immune-mediated inflammatory disorders
A1 Martínez-Hernández, Rebeca
A1 Fuente, Hortensia de la
A1 Lamana Domínguez, Amalia
A1 Sampedro-Núñez, Miguel
A1 Ramos-Levi, Ana
A1 Serrano-Somavilla, Ana
A1 García-Vicuña, Rosario
A1 Ortiz, Ana
A1 Daudén, Esteban
A1 Llamas-Velasco, Mar
A1 Chicharro, Pablo
A1 Rodríguez-Jiménez, Pedro
A1 Sanz-García, Ancor
A1 Sánchez-Madrid, Francisco
A1 González-Álvaro, Isidoro
A1 Marazuela, Mónica
AB Immune-mediated inflammatory disorders (IMID) are a group of diseases that present inflammation as a major pathogenic mechanism. They affect 15% of the population and pose a heavy socio-economic burden. Despite the growing knowledge on the etiopathogenesis of these diseases and the marked improvement in their management, there is a lack of predictive markers of IMID development or severity suitable for early diagnosis and adjustment of treatment intensity. The possibility that certain circulating miRNA profiles could be used as biomarkers of risk of development and/or severity of several autoimmune diseases has fuelled the interest in using them to improve the selection of successful treatments. The multi-pronged approach proposed here sought to reveal circulating miRNAs and miRNA signatures that could act as new predictive biomarkers of IMID development and severity. Our results showed that the circulating levels of miR-19b and miR-26b were significantly decreased (p < 0.001) in IMID patients compared to controls. Furthermore, receiver operating characteristic (ROC) curve analysis showed that these miRNAs were suitable discriminators capable to identify an IMID, with areas under the curve (AUC) of 0.85 and 0.83, respectively. In addition, we established that miR19a and miR-143 were significantly increased in IMID patients with severe disease (p < 0.05). In summary, our findings identify two different miRNA signatures. One of them is associated with the presence of IMIDs and could lead to the development of tools for their early detection. The second signature is able to discriminate between mild and severe forms of these disorders and could be a putative tool to select patient candidates for a more intense treatment.
SN 0896-8411
YR 2020
FD 2020
LK https://hdl.handle.net/20.500.14352/94199
UL https://hdl.handle.net/20.500.14352/94199
LA eng
NO Martínez-Hernández, Rebeca, et al. «Utility of Circulating Serum miRNA Profiles to Evaluate the Potential Risk and Severity of Immune-Mediated Inflammatory Disorders». Journal of Autoimmunity, vol. 111, julio de 2020, p. 102472. https://doi.org/10.1016/j.jaut.2020.102472.
NO This work was supported by the following grants: Proyectos de Investigación en Salud (FIS) PIE13-0041, PI16-02091 and PI19-00584 (funded by Ministerio de Economía y Competitividad (MINECO), Instituto de Salud Carlos III (ISCIII)), TIRONET2-CM, B2017/BMD-3724 (funded by Comunidad de Madrid), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER GCV14/ER/12) to MM; also by grants RD16/0011/0012 and PI18/0371 from MINECO, ISCIII to IGA; PI17/01972 (MINECO, ISCIIII) to E. D; and Plan Nacional de Salud SAF2017-82886-R, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Fundación BBVA a equipos de Investigación Científica 2018 and from “la Caixa Banking Foundation” under the project code HR17-00016 to F·S.M and cofinanced by FEDER funds.
NO Comunidad de Madrid
NO Ministerio de Economía y Competitividad (España)
NO Fundación La Caixa
NO Instituto de Salud Carlos III
NO Centro de Investigación Biomédica en Red de Enfermedades Raras
DS Docta Complutense
RD 20 abr 2025